Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × Interleukin 1 Receptor Antagonist Protein × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 241 Carboplatin 134 Nivolumab 131 Gemcitabine 124 Paclitaxel 116 Cisplatin 104 Bevacizumab 95 Cyclophosphamide 90 Dexamethasone 76 Injections 75 Docetaxel 71 Pemetrexed 69 Fluorouracil 68 Capecitabine 64 Rituximab 61 atezolizumab 60 Cetuximab 60 Oxaliplatin 58 130-nm albumin-bound paclitaxel 58 Leucovorin 56 Ipilimumab 51 Lenalidomide 46 fludarabine 42 Azacitidine 40 Irinotecan 39 venetoclax 38 Albumin-Bound Paclitaxel 36 Prednisone 35 Fulvestrant 35 Trastuzumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03430011 2024-05-24

EVOLVE

Juno Therapeutics, a Subsidiary of Celgene

Phase 1/2 Completed

165 enrolled 38 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡